MedTrace Logo

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

NCT05891769 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-10

No results posted yet for this study

Summary

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT

Conditions

  • Parathyroid Adenoma

Interventions

DRUG

18Fluorocholine

18F Fluorocholine 5 mCi ± 20% administered intravenously.

Sponsors & Collaborators

  • Andrei Iagaru

    lead OTHER

Principal Investigators

  • Andrei Iagaru, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2026-07-01
Completion
2027-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891769 on ClinicalTrials.gov